Immunotherapy after chemo may keep aggressive lymphoma at bay
NCT ID NCT03463057
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether the immunotherapy drug atezolizumab can help prevent relapse in people with high-risk diffuse large B-cell lymphoma (DLBCL) who have already achieved remission with standard chemotherapy (R-CHOP). About 109 adults aged 18–75 are receiving 18 cycles of atezolizumab followed by 12 months of observation. The main goal is to see if this approach improves disease-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (Tecentriq)
What this could lead to
If it works, this could offer a way to keep high-risk DLBCL in remission longer after initial chemotherapy.
What could go wrong
This is a mid-stage trial with only 109 participants, so results may not apply to everyone. Atezolizumab can cause immune-related side effects, and it's unclear if it will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BE-Antwerpen Edegem-UZA
Antwerp, Belgium
-
BE-Antwerpen-ZNASTUIVENBERG
Antwerp, Belgium
-
BE-Brugge-AZBRUGGE
Bruges, Belgium
-
BE-Leuven-UZLEUVEN
Leuven, Belgium
-
BE-Roeselare-AZDELTA
Roeselare, Belgium
-
NL-Amersfoort-MEANDERMC
Amersfoort, Netherlands
-
NL-Amsterdam-OLVG
Amsterdam, Netherlands
-
NL-Amsterdam-VUMC
Amsterdam, Netherlands
-
NL-Apeldoorn-GELREAPELDOORN
Apeldoorn, Netherlands
-
NL-Breda-AMPHIA
Breda, Netherlands
-
NL-Delft-RDGG
Delft, Netherlands
-
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands
-
NL-Den Haag-HAGA
The Hague, Netherlands
-
NL-Dordrecht-ASZ
Dordrecht, Netherlands
-
NL-Ede-ZGV
Ede, Netherlands
-
NL-Eindhoven-CATHARINA
Eindhoven, Netherlands
-
NL-Eindhoven-MAXIMAMC
Eindhoven, Netherlands
-
NL-Enschede-MST
Enschede, Netherlands
-
NL-Groningen-UMCG
Groningen, Netherlands
-
NL-Hilversum-TERGOOI
Hilversum, Netherlands
-
NL-Hoofddorp-SPAARNEGASTHUIS
Hoofddorp, Netherlands
-
NL-Leeuwarden-MCL
Leeuwarden, Netherlands
-
NL-Leiden-LUMC
Leiden, Netherlands
-
NL-Maastricht-MUMC
Maastricht, Netherlands
-
NL-Nieuwegein-ANTONIUS
Nieuwegein, Netherlands
-
NL-Nijmegen-CWZ
Nijmegen, Netherlands
-
NL-Rotterdam-ERASMUSMC
Rotterdam, Netherlands
-
NL-Rotterdam-MAASSTADZIEKENHUIS
Rotterdam, Netherlands
-
NL-Sittard-Geleen-ZUYDERLAND
Sittard, Netherlands
-
NL-Tilburg-ETZ
Tilburg, Netherlands
-
NL-Utrecht-UMCUTRECHT
Utrecht, Netherlands
-
NL-Zwolle-ISALA
Zwolle, Netherlands